- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT03049397
Enhancing Connections Program in Improving Family Adjustment in Patients With Incurable Cancer
Family Functioning and Bereavement Outcomes Following the Enhancing Connections Program in Palliative Care
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
PRIMARY OBJECTIVES:
I. Test the feasibility of the study protocol in advanced cancer patients and co-parents (recruitment/retention, dosage and fidelity of the intervention; program acceptability of program; and logistics).
II. Evaluate the short-term impact of the program on the diagnosed parents', co-parents' and children's adjustment and family functioning using a within group design (pre- and posttest design).
III. Compare outcomes from the Enhancing Connections Palliative Program with similar outcomes obtained from the completed phase III trial (between group design) for the patients and children outcomes.
IV. Evaluate the longer term impact of the program on the co-parents' and children's adjustment, including bereavement outcomes when appropriate, using a within and across group design (pre- and posttest design).
OUTLINE:
Patients and co-parents participate in the Enhancing Connections program consisting of 5 sessions over 1 hour each in the clinic or over the telephone. Session topics include managing cancer-related emotions when talking to children, developing deep listening skills, initiating difficult cancer-related conversations with children, interpreting a child's behavior, recognizing newly acquired gains from the program, and identifying available resources that can be used after program completion.
After completion of the study, participants are followed-up at 6 months.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
Washington
-
Seattle, Washington, Stati Uniti, 98109
- Fred Hutch/University of Washington Cancer Consortium
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
PATIENTS
- Ages 25-65 years
- Have a diagnosis of incurable cancer of any type; at any time in the diagnosis as long as they have at least a 4 month life expectancy based on the opinion of the attending physician
- Read and write English among their languages of choice
- Parent must live at least 50% of the time in the home and have a child 5-17 years old living at home who has been told their parent's cancer diagnosis
CO-PARENTS
- Co-parents must reside with the consenting eligible cancer participant (and child) at least 50% of the time and be actively participating in the care of the child
- If a biological parent lives in the home, and is physically well themselves, this person must be the co-parent
- If a biological parent does not live in the home (or has died), the co-parent does not have to be a biological parent; therefore, co-parents may be step-parents, lesbian, gay, bi-sexual or transgender (LGBT) partners, grandparents, aunts, uncles, etc if they otherwise meet eligibility criteria
- He or she can read and write English among their languages of choice and agrees to attend the patient intervention sessions in person or by telephone
CHILDREN
- The patient and co-parent must agree to focus on the same child throughout the study and consent to have the child participate before the child's assent will be sought
- Children aged 5-13 years of age will participate with a waiver of assent
- Children aged 14-17 will assent to participate in the research study by signing a separate assent form
- Children of formal assenting age will be eligible to participate if they can read and write English among their languages of choice
ALL PARTICIPANTS
- Participants must live within 35 miles of the University of Washington, Seattle, WA to receive the in-person version of the intervention
- Parents and co-parents selecting the telephone version of the intervention may live any distance from the University of Washington
Exclusion Criteria:
- Patients will be excluded if they are enrolled in hospice at time of enrollment; however, they will be allowed to continue in the study if they enroll in hospice after beginning the study
- The triad will be ineligible if any member lives in the home less than 50% of the time
- If any member of the triad retracts consent or assent prior to completion of the post-intervention surveys, then all members will be excluded from the study thereafter
- The child will be excluded if he or she has learning challenges as assessed by the patient or co-parent; patients and co-parents will be instructed to consider any formal diagnoses of a learning disability of the presence of an Individual Education Plan (IEP) when making this assessment
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Terapia di supporto
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Supportive Care (Enhancing Connections program)
Patients and co-parents participate in the Enhancing Connections program consisting of 5 sessions over 1 hour each in the clinic or over the telephone.
Session topics include managing cancer-related emotions when talking to children, developing deep listening skills, initiating difficult cancer-related conversations with children, interpreting a child's behavior, recognizing newly acquired gains from the program, and identifying available resources that can be used after program completion.
|
Studi accessori
Complete Enhancing Connections program
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Feasibility of the Enhancing Connections program in advanced cancer patients and co-parents
Lasso di tempo: Up to 2 years
|
Recruitment and retention of all triads will be monitored.
Dosage and fidelity will be monitored for each intervention session.
Program acceptability (per session, overall, duration of program, interval between intervention sessions) will be assessed from a debriefing interview.
For logistics four areas will be monitored: rate of receipt of mailed materials both to participants and from participants; duration and type (whether telephone or in-person) of intervention sessions; rate of success in scheduling and completing intervention sessions with patient and co-parent; and quality of data on baseline, post-intervention and follow-up measures.
|
Up to 2 years
|
|
Change in adjustment and family functioning
Lasso di tempo: Baseline to 6 months
|
Descriptive statistics (e.g.
means, medians) will be used to describe the Enhancing Connections palliative care population.
Parents', co-parents and children's baseline scores [parent-reported] on standardized questionnaires will be compared with post-intervention and 6 month follow-up scores on the same measures.
|
Baseline to 6 months
|
|
Outcomes from the Enhancing Connections Palliative Program as measured by the Child Behavior Check List
Lasso di tempo: Up to 2 years
|
Linear mixed modeling based on Maximum Likelihood Estimation will be used to test the differences between the Child Behavior Check List results for the Enhancing Connections Palliative Program and the completed phase III trial (EC-R01).
|
Up to 2 years
|
|
Change in adjustment as measured by post-traumatic growth scores
Lasso di tempo: Baseline to 6 months
|
Enhancing Connection Palliative Program parents', co-parents' and children's post-traumatic growth scores will be compared with follow-up (6 month) scores on the same measure.
|
Baseline to 6 months
|
Collaboratori e investigatori
Sponsor
Collaboratori
Investigatori
- Investigatore principale: Elizabeth Loggers, Fred Hutch/University of Washington Cancer Consortium
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- 9667 (Altro identificatore: Fred Hutch/University of Washington Cancer Consortium)
- P30CA015704 (Sovvenzione/contratto NIH degli Stati Uniti)
- NCI-2016-01640 (Identificatore di registro: CTRP (Clinical Trial Reporting Program))
- RG9218011 (Altro identificatore: Fred Hutch/University of Washington Cancer Consortium)
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Neoplasia maligna avanzata
-
Rush University Medical CenterCompletatoAdvanced Cardiac Life Support, rianimazione cardiopolmonare, volume corrente, ventilazione manualeStati Uniti
-
The Leeds Teaching Hospitals NHS TrustAttivo, non reclutanteFerite e lesioni | Chirurgia | Riabilitazione | Disturbo ortopedico | Misure di esito riferite dal paziente | Valutazione della disabilità | Recupero della funzione | Trauma multiplo/lesioni | Centri traumatologici | Indici di gravità del trauma | Advanced Trauma Life Support CareRegno Unito
-
Yonsei UniversityNon ancora reclutamentoRAS/BRAF Wild-Type Advanced Cancer MathementCorea, Repubblica di
-
Advanced BionicsCompletatoPerdita dell'udito da grave a profonda | negli utenti adulti di Advanced Bionics HiResolution™ Bionic Ear SystemStati Uniti
-
University Health Network, TorontoNon ancora reclutamentoNeoplasia tonsillare | Neoplasia dell'orofaringe | Chirurgia robotica transoraleCanada
-
Second Affiliated Hospital, School of Medicine,...Attivo, non reclutanteElettroacopuntura combinata con paclitaxel legato alla proteina e anticorpo PD-1 per il trattamento di seconda linea di HER2 negativo, PMMR/MSS Advanced Gastric CancerCina
-
National University Hospital, SingaporeEDDC (Experimental Drug Development Centre), A*STAR Research EntitiesReclutamentoCon MSS/pMMR Advanced, cancro ovarico resistente al platinoSingapore
Prove cliniche su Amministrazione del questionario
-
Virginia Commonwealth UniversityRigel PharmaceuticalsReclutamentoLeucemia mieloide acutaStati Uniti
-
Cairn DiagnosticsCompletato
-
Nova Scotia Health AuthorityNon ancora reclutamento
-
University of California, San FranciscoNational Institute of Allergy and Infectious Diseases (NIAID); GlaxoSmithKline; Stanford University e altri collaboratoriReclutamentoMalaria | Plasmodium Vivax MalariaPerù
-
Pyae Linn AungUniversity of South Florida; Mahidol UniversityAttivo, non reclutanteMalaria | Plasmodium Vivax | Myanmar | Amministrazione farmaceutica di massa | PrimachinaBirmania
-
Brown UniversityCompletato
-
Universitas Negeri SemarangMinistry of Research, Technology and Higher Education, Republic of IndonesiaSconosciutoLo stress ossidativo | Sforzo; EccessoIndonesia
-
University Hospital PadovaCompletatoSindrome da distress respiratorio, neonatoItalia
-
Weill Medical College of Cornell UniversityNew York Presbyterian HospitalReclutamento
-
Washington University School of MedicineCompletatoFilariosi linfatica | Oncocercosi | Infezioni da elminti trasmessi dal suolo (STH).Liberia